6th Euro Virology Congress and Expo
Capital Medical University, China
Title: Inhaled IFN-α1b for RSV bronchiolitis
Biography: Shen Kunling
Respiratory syncytial virus (RSV) is the most common pathogeny of bronchiolitis and 90% children are infected with RSV in their first 2 years. Interferon-α1b is the main subtype of alpha interferon in Chinese and has been widely used in viral disease treatment. A series of preclinical and clinical studies were carried out to evaluate efficacy and safety of IFN-α1b against RSV by aerosol inhalation. Animal PK and tissue distribution study demonstrates that after administration via aerosol inhalation, large amount of 125I-IFN-α1b concentrates in airway and stays longer than intramuscular injection. In a PD study, RSV infected mice which receiving inhaled IFN-α1b treatment show less tissue damage and lower RSV load in lung and increased CD3+CD8+ lymphocyte level in peripheral blood compared with control group. Both anti-RSV and immunoregulation effects of IFN-α1b are in a dose-effect manner. In a multicenter RCT study recruiting 330 acute bronchiolitis children, the total improvement rates of nebulized IFN-α1b 2 μg/kg and 4 μg/kg were 92.3% and 95.0% respectively and significantly higher than control group (85.3%, P<0.05). The effect on symptoms improvement of higher dose group is better than lower dose. The efficacy of IFN-α1b is better when used in early stage of disease and for RSV positive children. Irritation symptoms and serious adverse reactions were not observed. In summary, inhaled IFN-α1b is effective and safe for anti-RSV bronchiolitis in children.